JP2018527011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527011A5 JP2018527011A5 JP2018514889A JP2018514889A JP2018527011A5 JP 2018527011 A5 JP2018527011 A5 JP 2018527011A5 JP 2018514889 A JP2018514889 A JP 2018514889A JP 2018514889 A JP2018514889 A JP 2018514889A JP 2018527011 A5 JP2018527011 A5 JP 2018527011A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- autoimmune
- specific
- antagonist polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003812 Interleukin-15 Human genes 0.000 claims 28
- 108090000172 Interleukin-15 Proteins 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 239000005557 antagonist Substances 0.000 claims 18
- 150000001413 amino acids Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 7
- 208000011580 syndromic disease Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 5
- 208000007465 Giant cell arteritis Diseases 0.000 claims 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 4
- 206010047115 Vasculitis Diseases 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010043207 temporal arteritis Diseases 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 229940009098 aspartate Drugs 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 208000021866 Dressler syndrome Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 208000012309 Linear IgA disease Diseases 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 206010042276 Subacute endocarditis Diseases 0.000 claims 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 claims 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010063409 Acarodermatitis Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010071577 Autoimmune hyperlipidaemia Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010019263 Heart block congenital Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 208000031814 IgA Vasculitis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000027601 Inner ear disease Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 208000017119 Labyrinth disease Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 241000447727 Scabies Species 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 claims 1
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 208000029407 autoimmune urticaria Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 201000004395 congenital heart block Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 208000002980 facial hemiatrophy Diseases 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000005687 scabies Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306418.3 | 2015-09-16 | ||
| EP15306418 | 2015-09-16 | ||
| PCT/EP2016/071759 WO2017046200A1 (en) | 2015-09-16 | 2016-09-15 | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527011A JP2018527011A (ja) | 2018-09-20 |
| JP2018527011A5 true JP2018527011A5 (enExample) | 2019-07-18 |
| JP6800219B2 JP6800219B2 (ja) | 2020-12-16 |
Family
ID=54252214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018514889A Expired - Fee Related JP6800219B2 (ja) | 2015-09-16 | 2016-09-15 | 特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10858452B2 (enExample) |
| EP (1) | EP3350205A1 (enExample) |
| JP (1) | JP6800219B2 (enExample) |
| WO (1) | WO2017046200A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| ES2778053T3 (es) | 2011-01-18 | 2020-08-07 | Bioniz Llc | Composiciones para modular la actividad de la citocina gamma-c |
| EP3359556B1 (en) | 2015-10-09 | 2021-05-26 | Bioniz, LLC | Modulating gamma - c -cytokine activity |
| EP3458092A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| KR20240142577A (ko) | 2017-04-07 | 2024-09-30 | 바이오니즈 테라퓨틱스, 아이엔씨. | 감마-c-사이토카인 활성의 안정한 조절자 |
| AU2018257917B2 (en) * | 2017-04-24 | 2023-05-04 | University Of Massachusetts | Diagnosis and treatment of vitiligo |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| CA3102821A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| CN112534052B (zh) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | 全新il-21前药及使用方法 |
| JP2022530677A (ja) * | 2019-05-03 | 2022-06-30 | バイオニズ リミテッド ライアビリティー カンパニー | 脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節 |
| JP7762570B2 (ja) | 2019-05-20 | 2025-10-30 | サイチューン ファーマ | 癌又は感染性疾患を処置するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト投薬レジメン |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| CN114302650B (zh) | 2019-07-03 | 2024-09-13 | 休斯敦大学体系 | Il-15抑制剂及其在治疗自身免疫/炎性病症中的用途 |
| JP7807076B2 (ja) * | 2019-12-13 | 2026-01-27 | キュージーン インコーポレイテッド | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| JP7767290B2 (ja) | 2020-01-11 | 2025-11-11 | アスクジーン・ファーマ・インコーポレイテッド | 新規なマスクされたサイトカインおよびその使用方法 |
| JP2023550685A (ja) | 2020-10-26 | 2023-12-05 | サイチューン ファーマ | 扁平上皮癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト |
| KR20230096047A (ko) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제 |
| IL309522B2 (en) | 2021-06-23 | 2025-12-01 | Cytune Pharma | Interleukin 15 variants |
| CA3225815A1 (en) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| EP4562059A1 (en) * | 2023-02-21 | 2025-06-04 | RemeGen Co., Ltd. | Il-15 agonists for cancer |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO2006017853A2 (en) | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| KR102539359B1 (ko) | 2013-04-19 | 2023-06-02 | 싸이튠 파마 | 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료 |
| SI3030262T1 (sl) | 2013-08-08 | 2020-03-31 | Cytune Pharma | Kombiniran farmacevtski sestavek |
| CA2919725C (en) | 2013-08-08 | 2023-04-18 | Cytune Pharma | An il-15 and il-15r.aplha. sushi domain based modulokines |
| EP2915569A1 (en) * | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
-
2016
- 2016-09-15 JP JP2018514889A patent/JP6800219B2/ja not_active Expired - Fee Related
- 2016-09-15 WO PCT/EP2016/071759 patent/WO2017046200A1/en not_active Ceased
- 2016-09-15 EP EP16769927.1A patent/EP3350205A1/en not_active Withdrawn
- 2016-09-15 US US15/754,664 patent/US10858452B2/en not_active Expired - Fee Related